Intranasal administration of mesenchymoangioblast-derived mesenchymal stem cells abrogates airway fibrosis and airway hyperresponsiveness associated with chronic allergic airways disease
0
likes
•
0
questions
•
0
company answers
Ask a question
Your question will be sent privately to Cynata Therapeutics. The company may choose to make this question public.
Investor Q&As
Start the conversation
Ask Cynata Therapeutics a question about this update.